Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 carrier cohort study

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 601-610

  Antoniou, Antonis C ^a,w   Rookus, Matti ^b   Andrieu, Nadine ^c,d   Brohet, Richard ^b   Chang Claude, Jenny ^e   Peock, Susan ^a   Cook, Margaret ^a   Evans, D Gareth ^f   Eeles, Rosalind ^g   Embrace, Catherine Nogues ^h   Faivre, Laurence ⁱ   Gesta, Paul ^j   Van Leeuwen, Genepso Flora E ^b   Ausems, Margreet G E M ^k   Geo Hebon, Ana Osorio ^l   Caldes, Trinidad ^m   Simard, Jacques ⁿ   Lubinski, Jan ^o   Gerdes, Anne Marie ^p   Olah, Edith ^q   Fürhauser, Christine ^r   Olsson, Hakan ^s   Arver, Brita ^t   Radice, Paolo ^u   Easton, Douglas F ^a   Goldgar, David E ^v   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c INSERM U900   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f ST MARY S HOSPITAL   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h CENTRE RENÉ HUGUENIN   (France)

ⁱ Medical University of Dijon   (France)

^j Oncogénétique Poitou Charentes ^*  (France)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l Centro Nacional de Investigaciones Oncológicas   (Spain)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁿ LAVAL UNIVERSITY   (Canada)

^o POMERANIAN MEDICAL UNIVERSITY   (Poland)

^p ODENSE UNIVERSITY HOSPITAL   (Denmark)

^q NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^r MEDICAL UNIVERSITY OF VIENNA   (Austria)

^s LUND UNIVERSITY HOSPITAL   (Sweden)

^t KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^u FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^v UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^w UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CANCER; PREGNANCY; PRIORITY JOURNAL;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; COHORT STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PARITY; PREGNANCY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STERILIZATION, TUBAL;

EID: 60549104788     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0546     Document Type: Article

References (34)

1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
2. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000;18:173-90.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
4. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
5. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706.
6. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776-81.
7. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
8. Milne RL, Osorio A, Cajal TR, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 2008;14:2861-9.
9. Beral V, Doll R, Hermon C, Peto R, Reeves G, Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemio-logical studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-14.
10. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-203.
11. Whittemore AS, Harris R, Itnyre J, Halpern J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. I. Methods. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1175-83.
12. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270:2813-8.
13. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996;5:933-5.
14. Gronwald J, Byrski T, Huzarski T, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006;95:105-9.
15. McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and non-carriers of BRCA1 gene mutations. Am J Epidemiol 2004;160:613-8.
16. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26-34.
17. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-40.
18. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-8.
19. Rutter JL, Wacholder S, Chetrit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 2003;95:1072-8.
20. Whittemore AS, Balise RR, Pharoah PD, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004;91:1911-5.
21. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347:1713-27.
22. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: a report from EMBRACE, GENEPSO, GEO-HEBON, the IBCCS Collaborating Group. J Clin Oncol 2007;25:3831-6.
23. Andrieu N, Goldgar D, Easton D, et al. Pregnancies, breastfeeding and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006;98:535-44.
24. Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2mutation carriers in the International BRCA1/2 Carrier Cohort Study: a report from the EMBRACE, GENEPSO, GEO-HEBON, IBCCS Collaborators' Group. J Clin Oncol 2006;24:3361-6.
25. Chang-Claude J, Andrieu N, Rookus M, et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2007;16:740-6.
26. Goldgar D, Bonnardel C, Renard H, Yaquobi O. The International BRCA1/2 Carrier Cohort Study: purpose, rationale, and study design. Breast Cancer Res 2000;2:E010.
27. Antoniou AC, Goldgar DE, Andrieu N, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 2005;29:1-11.
28. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
29. Nagle CM, Bain CJ, Green AC, Webb PM. The influence of reproductive and hormonal factors on ovarian cancer survival. Int J Gynecol Cancer 2008;18:407-13.
30. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001;357:1467-70.
31. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:1457-66.
32. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9.
33. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006;15:1863-70.
34. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2mutations. Cancer Epidemiol Biomarkers Prev 2005;14:350-6.